| Theme | Gastroenteropancreatic Neuroendocrine Tumors | |
|---|---|---|
| Title | Somatostatin Receptor Scintigraphy | |
| Publish Date | 2013/01 | |
| Author | Hajime Izumiyama | Tokyo Medical and Dental University Hospital, Diabetes, Endocrinology and Metabolism, and Center for Medical Welfare and Liaison Services |
| [ Summary ] | It has become clear that somatostatin suppresses all hormone secretion. As a result, somatostatin-analogs have been exploited as therapeutic medications. Because somatostatin receptors exist in neuroendocrine tumors, [111In]-pentetreotide, is a ligand associated with somatostatin receptor scintigraphy (SRS). It has come to be used for localized diagnosis of neuroendocrine tumors (NETs). SRS provides higher rates of tumor detection than examinations employing other types of images. SRS is useful for classification and staging of diseases. Results from SRS examinations may influence the choice of therapeutic medications. In addition, when positive images are observed with SRS, somatostatin analogs are useful as therapeutic medications. These patients may be able to receive treatments with peptide receptor radionuclide therapy. As a result, SRS should be implemented in patients with NET as often as possible. | |